Bold claim: dementia biomarkers can predict and track cognitive decline even before formal diagnosis, offering a clearer path through the uncertainty that haunts subjective memory concerns. And this is the part many overlook: early signals in blood tests could spotlight who is on a higher-risk trajectory, enabling proactive monitoring, prevention, and potential disease-modifying strategies.
Why biomarker insight matters when thoughts feel muddled but tests still look normal
People with subjective cognitive decline often notice memory lapses despite normal results on standard clinical tests. This puts them in a twilight zone between ordinary aging and the onset of disease. Biomarkers for dementia are increasingly viewed as tools to reduce that ambiguity. Blood-based tests are especially appealing: they’re less invasive than brain scans or spinal taps and easier to repeat over time. Researchers are hunting for reliable indicators that shift in tandem with brain health. If such markers prove dependable, clinicians could identify higher-risk individuals earlier, creating an opportunity for ongoing monitoring, lifestyle interventions, and, in the future, therapies that modify disease progression.
Longitudinal biomarker changes align with cognitive outcomes
In a prospective cohort study, 298 individuals with subjective cognitive decline were assessed at a memory clinic from January 1, 2005, to December 31, 2023. The average age was about 61.6 years, with 58% male. Eighty participants were amyloid-positive, while 218 were amyloid-negative. Follow-up averaged 4.8 years. At baseline, levels of pTau 217, GFAP, and neurofilament light were higher in the amyloid-positive group, with statistically significant differences for amyloid beta (1.11 [0.11]), GFAP (0.69 [0.13]), and neurofilament light (0.36 [0.10]). All three biomarkers rose more steeply over time in amyloid-positive individuals. A faster increase in pTau 217 was linked to progression to mild cognitive impairment or dementia, with a hazard ratio of 3.6 per 0.05 SD annual slope (95% CI 1.8–7.4). Accelerated GFAP and neurofilament light slopes similarly correlated with progression. Notably, about 20% of participants who started biomarker-negative converted to positive during follow-up.
Practical implications for clinicians and future monitoring
For clinicians, these findings endorse using repeated, blood-based dementia biomarkers to stratify risk over time and to monitor disease progression. Serial testing could flag patients who need closer cognitive follow-up, earlier lifestyle interventions, and faster access to potential disease-modifying treatments as they become available. As more therapies targeting early Alzheimer pathology emerge, dementia biomarkers are poised to play an expanding role in guiding timely clinical decisions.
Reference
Trieu C et al. Longitudinal blood-based biomarkers and clinical progression in subjective cognitive decline. JAMA Netw Open. 2025;8(12):e2545862.
Author note:
This article is shared under the Creative Commons Attribution-Non Commercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/).
